Antimicrobial Resistance – Navigating obstacles in R&D and commercialization
The lack of innovation surrounding the development of new antibiotics has resulted in an alarming situation, given the rising threat of antimicrobial resistance (AMR).
As a result, there is no single or straightforward way to combat AMR, nor to galvanize development of novel antibiotics. Although some positive measures have been introduced, further – and larger scale – action is needed.
Since the initial era of discovery in the mid-20th century, there has been a lackluster level of innovation in the antibiotics field, and today there are few novel antibiotic classes in development despite the urgency of medical need.
The lagging antimicrobial innovation has certainly made its impact felt. Estimates suggest that resistant infections underlie nearly 700,000 global deaths each year – a figure projected by some to rise to 10 million each year by 2050.
New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases, resulting in prolonged illness, disability, and death. Each year in the US alone, the CDC reports that at least 2 million people contract an antibiotic-resistant infection, with an estimated annual attributable death toll of 23,000.
You may also be interested in…
A message from our Chairwoman
At Deallus we are fortunate to have Ulrike Meier as our Chairwoman since 2020. Ulrike has written a brilliant blog reflecting on her time with Deallus so far and shares some insights into, even if removed from daily business, as Chairwoman, there is room to make a difference. From being authentic, focusing on the bigger picture, to providing motivation and guidance, Ulrike explores what key elements she prioritises in her role and how we can all play a part in organisation success.
World Immunization Week 2024
Decades of transformation, fueled by unprecedented innovation are continuously pushing the bar for what the vaccines industry needs to deliver. A tight balance of public and global health commitments, and commercial attractiveness.
Unlocking Insights at PharmaCI: A Recap from Deallus
At Deallus, we constantly strive to immerse ourselves in the latest developments and conversations within the competitive intelligence (CI) landscape. Recently, we had the privilege of attending PharmaCI in Munich, where we engaged in enriching discussions with esteemed clients, peers, and colleagues.